SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-22-189526
Filing Date
2022-07-07
Accepted
2022-07-07 16:57:01
Documents
2
Group Members
HIBERNIA MERGER SUB, INC.IPSEN BIOPHARMACEUTICALS, INC.IPSEN PHARMA SAS

Document Format Files

Seq Description Document Type Size
1 SC 13D d329747dsc13d.htm SC 13D 162215
2 EX-99.1.04 d329747dex99104.htm EX-99.1.04 6226
  Complete submission text file 0001193125-22-189526.txt   170025
Mailing Address 42, RUE DU DOCTEUR BLANCHE PARIS I0 75016
Business Address 42, RUE DU DOCTEUR BLANCHE PARIS I0 75016 011 33144961010
Ipsen, S.A. (Filed by) CIK: 0001370483 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139 617-229-5872
Epizyme, Inc. (Subject) CIK: 0001571498 (see all company filings)

IRS No.: 261349956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-87481 | Film No.: 221072179
SIC: 2834 Pharmaceutical Preparations